Type
Blood Testing
Duration
2 hours
Sample
Blood (venous draw) + ultrasound
What's included
3 deliverables in this treatment
- Venous blood draw for PAPP-A and free β-hCG at 9–10 weeks gestation
- Specialist nuchal translucency ultrasound at 11–14 weeks gestation
- Individual risk calculation and results counselling by G-CENTRUM perinatologist
The basic first-trimester combined screening at G-CENTRUM Olomouc combines a blood test and a nuchal translucency ultrasound to calculate each individual woman's risk of fetal chromosomal conditions including Down syndrome (Trisomy 21), Edwards syndrome (Trisomy 18), and Patau syndrome (Trisomy 13). The blood draw (measuring PAPP-A and free β-hCG hormones) is taken at 9–10 weeks of pregnancy; the ultrasound measurement of nuchal translucency — the fluid-filled space at the back of the fetal neck — follows at 11–14 weeks. Both results are combined with maternal age and pregnancy data to produce a personalised risk figure.
About this treatment
First-trimester combined screening is the internationally recommended standard for early chromosomal risk assessment in pregnancy, offering substantially higher detection rates than blood testing or ultrasound alone. At G-CENTRUM Olomouc, the screening is conducted in two coordinated steps integrated into the clinic's prenatal care pathway.
Step one (9–10 weeks): A venous blood draw measures two serum biomarkers — PAPP-A (pregnancy-associated plasma protein A) and free β-hCG (free beta human chorionic gonadotrophin). These hormones are produced by the placenta, and their levels deviate from the expected range in pregnancies affected by Trisomy 21 (Down syndrome), Trisomy 18 (Edwards syndrome), and Trisomy 13 (Patau syndrome).
Step two (11–14 weeks): A specialist at G-CENTRUM performs the nuchal translucency (NT) ultrasound, measuring the fluid accumulation at the back of the fetal neck. Increased NT thickness is associated with chromosomal abnormalities and certain structural conditions. The measurement requires a precisely dated pregnancy and a technically proficient operator — G-CENTRUM's perinatology team has extensive experience in first-trimester fetal ultrasound.
Good to know
- Detection rate
- ~85–90% for Trisomy 21
- Blood draw timing
- 9–10 weeks gestation
- Ultrasound timing
- 11–14 weeks gestation
- Conditions screened
- Trisomy 21, 18, 13
Who is this for?
All pregnant women at 11–14 weeks seeking early non-invasive risk assessment for chromosomal conditions
Preparation required
Schedule the blood draw at 9–10 weeks gestation. The nuchal translucency ultrasound will be booked for 11–14 weeks. No fasting required. Bring your pregnancy documentation and a doctor's referral.
About the clinic
Reviews, team and credentials
Independent review links and clinic-reported team information.
Clinical team
G-CENTRUM Olomouc is led by founder MUDr. Aleš Skřivánek, Ph.D., a gynecologist with over 35 years of clinical experience practicing since 1989. The team includes MUDr. Iveta Humlová, MUDr. Eva Hajkrová, MUDr. Jana Jelínková, and MUDr. Tomáš Kilián for outpatient gynecology and prenatal care. Urogynecology is covered by MUDr. Radovan Vrtal, Ph.D. and MUDr. Lukáš Kučera. Infertility diagnosis is managed by MUDr. Jan…
Languages: cs, en
What clients say
"{"author":"Andrea Musálková","text":"Pan doktor je velmi profesionální, vše dokáže dokonale vysvětlit i poradit. Má super lidský přístup.","platform":"ZnámýLékař.cz","translated":"The doctor is very professional, can explain everything perfectly and give advice. He has a great human approach."}"
"{"author":"NŠ","text":"Nejlepší gynekolog široko daleko. Pan doktor opravdu ví, co dělá.","platform":"ZnámýLékař.cz","translated":"The best gynecologist far and wide. The doctor really knows what he is doing."}"
Treatment highlights
- Venous blood draw for PAPP-A and free β-hCG at 9–10 weeks gestation
- Specialist nuchal translucency ultrasound at 11–14 weeks gestation
+1 more item in What's included
1,700 Kč total for the full combined screening — includes blood draw (PAPP-A + free β-hCG) at 9–10 weeks and nuchal translucency ultrasound at 11–14 weeks, plus individual risk calculation. Both appointments are needed to complete the test.